Trim 30-35% to lock in gains ahead of binary Q3 earnings catalyst; retain 65-70% with hard stop at $598
Underweight justified by fundamental+technical convergence at binary catalyst: FCF compression, leverage at 3.28x, forward P/E 24.6x in top decile of 18-22x historical range, price $33 above $645 consensus target, and $73.4B goodwill at 64.8% of assets with negative tangible book. Structural thesis intact ($5.7B+ FCF, 0.85 defensive beta, 90% recurring consumables, $1B+ buyback) supports retaining 65-70% rather than selling outright. CSP strategy at $620-640 strikes rejected due to inadequate premium-to-risk in hostile macro with 30-year yields at 2004 highs and 92% Polymarket odds of further Fed hikes.
| Position | Action |
|---|---|
| 5+ extension signals co-occurring (RSI 74.76, above Bollinger upper band $676.93, ATR expansion 14%, price +22% above 200 SMA, MACD late-stage expansion) | Apply 50% weight ceiling; trim 30-35% of holdings |
| Post-trim capital deployment | Deploy 50% into short-duration Treasuries (4.5%+ risk-free yield) and 50% into cash for tactical redeployment |
| Remaining position protection | Hard stop at $598 close (50 SMA structural break) |
TMO is a quality-growth compounder with institutional accumulation driving a fundamental re-rating, supported by accelerating Q2 earnings, strategic acquisitions (Olink, Mayo Clinic Precure JV), and ~$839 analyst target representing ~24% upside from current levels.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $538.33 | bullish |
| 50 SMA | $598.77 | bullish |
| 10 EMA | $648.97 | bullish |
| RSI | 74.76 | neutral |
| MACD Line | +19.10 | bullish |
| MACD Signal | +14.90 | bullish |
| MACD Histogram | +4.20 | bullish |
| ATR | $16.21 | bullish |
Support: 648.97 · 628.81 · 616.63 · 608.07 · 598.77 · 580.69 | Resistance: 671.47 · 676.93 · 682.98
TMO exhibits a robust bullish breakout structure with price far above all moving averages (200 SMA +26%, 50 SMA +13.3%, 10 EMA +4.5%), confirming strong long-term, medium-term, and short-term uptrends. Momentum indicators are overwhelmingly bullish: MACD crossed above its signal on 9/15 with the histogram expanding from -4.88 to +4.20 in two weeks, while RSI at 74.76 remains overbought but lacks bearish divergence. The ATR of $16.21 (2.4% of price) shows orderly volatility expansion, distinguishing this from a blow-off top. Strategic bias recommends holding core positions with trailing stops at the 50 SMA ($598.77) or 1.5x ATR (~$654), while new entrants should wait for pullbacks to the 10 EMA ($648.97) or Bollinger middle ($628.81) rather than chasing at current levels.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price pulls back to $595-605 on confirmed pullback with declining volume
Then: Re-enter trimmed position tactically
Valuation is justified by accelerating earnings and high-quality growth
EV: +24% · concedes: TTM P/E of 36.55x is elevated; Net debt has stepped up to $38.5B from $29.5B at YE25 post-Olink ($8.87B); Net debt/EBITDA is ~3.3x (rising leverage); China/Biosecure Act risk and biotech funding cyclicality acknowledged; 10-year yields at 2007 highs, 30-year above 5%, Fed pricing 92% odds of another hike, 97% no-cuts in 2026
TMO is a sell into strength at $678 because the stock has detached from fundamental value at a 24.6x forward P/E in the 90th percentile of its historical range, faces the worst rate environment in 17 years with 92% odds of further Fed hikes, and carries $73.4B in goodwill against negative tangible book value—creating an asymmetric risk profile ahead of Q3 earnings.
EV: -$8% to -20% from $678 · concedes: Technical trend is up; price is above all major moving averages; Q2 2026 earnings showed acceleration (+10.5% rev, +9.3% EPS y/y); FCF generation is excellent at $6.24B and 90% conversion; Macro environment hasn't killed the stock yet; Mayo partnership is real and strategically interesting; Q2 actual EPS of $4.68 confirmed some earnings power; Stock has rallied +55% in 4 months — momentum is real
→ vs conservative: Hold argument turns 50% winners into break-even trades; institutional holder bullishness is a distribution signal, not a buy signal; momentum 'intact until it isn't' leads to 10-15% drawdown before reaction
→ vs neutral: Passive 'wait for confirmation' strategy costs money; trim-into-rallies approach is reactive not proactive; waiting for 5-8% pullback to $610-625 is chasing a setup we can engineer with put sales
Market Cap
$250.83 B
TTM P/E
36.55x
Forward P/E
24.63x
PEG Ratio
1.98
Price / Book
4.76x
52-Week High
$682.98
52-Week Low
$435.27
50-Day MA
$598.76
200-Day MA
$539.16
EPS (TTM)
$18.56
Forward EPS
$27.54
Dividend Yield
0.28%
Beta
0.85
TTM Revenue
$46.34 B
TTM Gross Profit
$18.99 B
TTM EBITDA
$11.74 B
TTM Net Income
$6.97 B
Profit Margin
15.04%
Operating Margin
18.75%
Return on Equity
13.52%
Return on Assets
5.13%
Free Cash Flow (TTM)
$6.24 B
Revenue 2022
$44,915 M
Revenue 2023
$42,857 M
Revenue 2024
$42,879 M
Revenue 2025
$44,557 M
Net Income 2022
$6,950 M
Net Income 2023
$5,995 M
Net Income 2024
$6,335 M
Net Income 2025
$6,704 M
Diluted EPS 2022
$17.63
Diluted EPS 2023
$15.45
Diluted EPS 2024
$16.53
Diluted EPS 2025
$17.74
Diluted EPS Q2'25
$4.28
Diluted EPS Q3'25
$4.27
Diluted EPS Q4'25
$5.21
Diluted EPS Q1'26
$4.43
Diluted EPS Q2'26
$4.68
Cash & ST Investments 6/30/26
$4,064 M
Cash & ST Investments 12/31/25
$10,105 M
Total Debt 6/30/26
$42,549 M
Net Debt 6/30/26
$38,485 M
Net Debt 12/31/25
$29,533 M
Net Debt 12/31/24
$27,266 M
Stockholders' Equity 6/30/26
$52,680 M
Goodwill + Intangibles 6/30/26
$73,438 M
Goodwill 6/30/26
$54.8 B
Tangible Book Value 6/30/26
($20,758) M
Current Ratio 6/30/26
1.55
Debt / Equity 6/30/26
0.81
Net Debt / EBITDA
~3.3x
Free Cash Flow 2024
$7,267 M
Free Cash Flow 2025
$6,293 M
Buybacks 2024
$4,000 M
Buybacks 2025
$3,000 M
Acquisitions (net) 2025
$4,037 M
Acquisitions (net) TTM
~$12,910 M
Olink Acquisition Cost
$8.87 B
Gross Margin
41.0%
Net Margin
15.04%
vs. 200-DMA
~+27%
Strengths
Concerns
TMO is a high-quality defensive growth compounder operating through Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services segments. After a 2023 COVID-related trough, the company has staged a clean recovery with 2025 EPS at a new high of $17.74 and Q2 2026 confirming double-digit earnings acceleration (+9.3% y/y EPS). The valuation is premium (TTM P/E 36.55x, Forward P/E 24.63x) with strong FCF generation ($6.24 B TTM, ~90% conversion), but rising net debt ($38.5 B, ~3.3x net debt/EBITDA) and negative tangible book value ($20.8 B) reflect heavy acquisition-dependent growth. No formal BUY/HOLD/SELL rating is issued in the source report; the analyst awaits additional technical, peer comparison, and macro inputs before a final recommendation.
Macro: Hostile macro environment for long-duration equities: 10-year UST yield hit highest since 2007 on Sept 23, 30-year at highest since 2004 (back above 5%). Polymarket pricing implies 92% odds of at least one more Fed hike in 2026, 97% odds of no rate cuts in 2026. Jamie Dimon (JPM) warns \"it's not clear to me we've slayed inflation.\" Trump-Xi meeting and tentative Hormuz deal hopes are partially easing geopolitical risk premium with oil easing toward $100. US recession odds by end of 2026 at 10% (Polymarket). Global recession risk contained but rate path remains the bigger risk for equity multiples.